Jhalak Dholakia, MD, Highlights Promise of Neoadjuvant Carboplatin/Mirvetuximab Soravtansine in Advanced Ovarian Cancer
Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.
In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Jhalak Dholakia, MD, a fellow at the University of Alabama, discussed the promise of carboplatin and mirvetuximab soravtansine as a neoadjuvant treatment for folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.
In particular, Dholakia explained that if findings from the ongoing phase 2 study (NCT04606914) assessing the combination prove to be positive, it will be exciting to have a neoadjuvant targeted therapy available for this patient population.
Transcript:
It’s really exciting that we could use targeted therapy in the neoadjuvant setting [for patients with advanced-stage disease]. This is a new, exciting place that we’re going in gynecologic oncology and in ovarian cancer. I could very conceivably see this being used for other targeted therapies or other agents in order to really do the most we can up front with the most information we have for our patients.
Reference
Dholakia J. Single-arm phase II trial of carboplatin and mirvetuximab soravtansine as neoadjuvant chemotherapy (NACT) for advanced-stage ovarian, fallopian tube or primary peritoneal cancer (EOC) who are folate receptor a positive (NCT04606914). Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.
